Groups urge CMS to reconsider Epo policy

Why This Topic Matters

The policy change has potential implications for oncology treatment workflows, Medicare reimbursement, and office-based administration of supportive care drugs. It also highlights how coverage policy, clinical guidance, and federal oversight can diverge and affect patient care and practice operations.

Article Sections

1. CMS policy and oncology response

   Summarizes the Medicare coverage decision and the concerns raised by oncology stakeholders. It also introduces the scope of the policy and the setting in which it applies.

2. CMS response

   Describes the agency’s stated basis for reconsidering the policy and the types of evidence CMS says it wants to review. It also notes the professional society response and related federal correspondence.

3. One practice's experience

   Shares a physician office perspective on how the policy may affect patient management and practice operations. It focuses on billing, transfusion concerns, and communication with patients.

4. Get Congress involved

   Covers the congressional resolution introduced to oppose the policy and the broader legislative and regulatory attention the issue received. It also mentions anticipated FDA review activity.